According to the results of the SHOCK trial, ERV is now a class I indication for this patient population in the ACC/AHA myocardical infarction guidelines. [22] Mortality with CABG was similar to ...

Exclusion criteria included ventricular septal rupture, cardiac tamponade, severe valvular disease, isolated right ventricular CS, known dilated cardiomyopathy, shock from other causes (e.g ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more than half, according to a study published in Critical Care Nurse.

The book focuses on providing key practical information on treatment techniques for busy CUU personnel and features some important topics such as shock, sever sepsis, echocardiography, catheter-based ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

SCAI Stage C cardiogenic shock is characterized by significant ... in earlier studies by improving systolic blood pressure ...

Pham Van Quang, head of the Intensive Care and Anti-Poisoning Department, determined that the girl was suffering from ...

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...

Similarly, the Impella 5.5 with SmartAssist System is approved for short-term use of up to 14 days for paediatric patients weighing at least 30kg, also addressing cardiogenic shock under similar ...